Biotech part­ner drops Glax­o­SmithK­line’s ad­ju­vant as it moves Covid-19 vac­cine in­to PhII/III, cit­ing ‘man­u­fac­tur­ing con­sid­er­a­tions’

When Glax­o­SmithK­line re­vealed that its Sanofi-part­nered re­com­bi­nant pro­tein-based Covid-19 vac­cine pro­gram was run­ning in­to a ma­jor de­lay, the phar­ma gi­ant tucked in a para­graph not­ing the oth­er low­er-pro­file col­lab­o­ra­tions it had go­ing on that uti­lized its pan­dem­ic ad­ju­vant.

One of those part­ner­ships, though, is now com­ing to an end.

Chi­na’s Clover Bio­phar­ma­ceu­ti­cals — the first biotech to take up GSK’s of­fer to test its ad­ju­vant sys­tem with vac­cine can­di­dates back in Feb­ru­ary — said it’s go­ing to en­ter Phase II/III with an ad­ju­vant from Dy­navax in­stead.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.